Core Insights - The company Jianerkang (603205) reported a decline in total revenue and net profit for the first half of 2025, with total revenue at 466 million yuan, down 7.6% year-on-year, and net profit at 48.15 million yuan, down 21.0% [1][3] - The second quarter showed a more significant decline, with total revenue of 225 million yuan, down 23.01% year-on-year, and net profit of 19.34 million yuan, down 46.25% [1] - The company's accounts receivable is notably high, with accounts receivable accounting for 162.43% of the latest annual net profit [1][3] Financial Performance - Total revenue for 2024 was 505 million yuan, compared to 466 million yuan in 2025, reflecting a decrease of 7.6% [1] - Net profit decreased from 60.94 million yuan in 2024 to 48.15 million yuan in 2025, a decline of 21.0% [1] - The gross margin improved to 24.16%, up 6.91% year-on-year, while the net margin decreased to 10.33%, down 14.5% [1] - Total expenses (selling, administrative, and financial) amounted to 30.82 million yuan, representing 6.61% of revenue, an increase of 62.69% year-on-year [1] - Earnings per share fell from 0.52 yuan in 2024 to 0.31 yuan in 2025, a decrease of 40.38% [1] Cash Flow and Debt - The company reported cash assets of 743 million yuan, a significant increase of 151.52% from the previous year [1] - Accounts receivable slightly decreased from 200 million yuan to 195 million yuan, a decline of 2.25% [1] - The company has interest-bearing debt of 3.77 million yuan, indicating a manageable level of debt [1] Return on Investment - The company's Return on Invested Capital (ROIC) for the previous year was 9.73%, which is considered average [3] - Historical data shows a median ROIC of 21.46% since the company went public, indicating strong investment returns in the past [3] - The net profit margin for the previous year was 11.5%, suggesting average added value from products or services [3]

Meeting Overview - The second board meeting of Jianerkang Medical Technology Co., Ltd. was held on August 28, 2025, with all 9 directors present, complying with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the full and summary reports for the 2025 semi-annual report, with a unanimous vote of 9 in favor [2]. - The board also approved the special report on the storage and use of raised funds for the first half of 2025, again with a unanimous vote of 9 in favor [2]. - A resolution was passed to change the company's registered capital, abolish the supervisory board, and amend the company's articles of association, with a unanimous vote of 9 in favor. This change aligns with the new Company Law effective from July 1, 2024 [3][4]. - The board approved the revision and formulation of several governance systems to enhance operational standards and governance structure, with a unanimous vote of 9 in favor [4]. - A proposal to convene the first extraordinary general meeting of shareholders in 2025 was also approved, with a unanimous vote of 9 in favor [5].

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 16, 2025, at 14:30 [1] - The meeting will take place at the office building on the first floor, No. 1 Jiekang Road, Industrial Concentration Zone, Zhiqi Town, Jintan District, Changzhou City, Jiangsu Province [1] - Shareholders can vote through the Shanghai Stock Exchange's online voting system from 9:15 to 15:00 on the day of the meeting [1][2] Voting Procedures - The voting will be conducted through a combination of on-site and online voting methods [2] - Shareholders must register to attend the meeting and can authorize a representative to vote on their behalf [4] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [3] Agenda Items - The meeting will review proposals that have been approved by the company's second board of directors [2] - Key proposals include changes to the company's registered capital and the cancellation of the supervisory board [2][8] Attendance Requirements - Shareholders must be registered by the close of trading on September 9, 2025, to attend the meeting [3] - Required documents for registration include proof of shareholding and identification [4] Contact Information - For inquiries, shareholders can contact the Securities Department at 0519-82446601 or via email at lp@chinajek.com [5]

Group 1 - The second meeting of the supervisory board of Jianerkang Medical Technology Co., Ltd. was held on August 28, 2025, with all three supervisors present, complying with relevant laws and regulations [1][2] - The supervisory board approved the 2025 semi-annual report, confirming that the report's preparation and review processes were legal and compliant, and accurately reflected the company's financial status and operational results [1][2] - The supervisory board also approved the special report on the use of raised funds for the first half of 2025, stating that the company adhered to legal procedures and that there were no significant risks associated with the use of these funds [2]

Core Insights - The company Jianerkang reported a decrease in the number of shareholders to 18,173 as of June 30, 2025, a reduction of 40 shareholders or 0.22% compared to June 20, 2025 [1][2] - The average number of shares held per shareholder increased slightly from 6,589 shares to 6,603 shares, with an average market value of 255,100 yuan per shareholder [1][2] - Compared to the medical device industry average, Jianerkang's shareholder count is below the industry average of 21,900 shareholders, and its average market value per shareholder is also lower than the industry average of 469,300 yuan [1][2] Stock Performance - From June 20 to June 30, 2025, Jianerkang's stock price increased by 4.01%, despite a decrease in the number of shareholders [1][2] - During this period, the company experienced a net outflow of 25.49 million yuan from institutional investors and a net outflow of 13.44 million yuan from retail investors, while retail investors saw a net inflow of 38.93 million yuan [2]

(三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025年9月16日 14 点30 分 召开地点：江苏省常州市金坛区直溪镇工业集中区健尔康路1号办公楼一楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025年9月16日 至2025年9月16日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的交易时间 段，即9:15-9:25,9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的9:15- 15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投票，应按照《上海证券交易 所上市公司自律监管指引第1号 一 规范运作》等有关规定执行。 (七)涉及公开征集股东投票权 不涉及 二、会议审议事项 本次股东大会审议议案及投票股东类型 ■ 1、各议案已披露的时间和披露媒体 本次提交股东大会审议的议案已经 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-021 健尔康医疗科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 16 日 14 点 30 分 召开地点：江苏省常州市金坛区直溪镇工业集中区健尔康路 1 号办公楼一楼 会议室 股东大会召开日期：2025年9月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 16 日 至2025 年 9 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-019 健尔康医疗科技股份有限公司 第二届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 健尔康医疗科技股份有限公司（以下简称"公司"）第二届监事会第八次会 议于 2025 年 8 月 28 日以现场结合通讯的方式在公司会议室召开，会议通知于 2025 年 8 月 18 日以书面等方式送达。本次会议由监事会主席汤红芳女士主持， 会议应到监事 3 人，实到监事 3 人。本次监事会的召集、召开和表决程序符合《中 华人民共和国公司法》等有关法律法规及《健尔康医疗科技股份有限公司章程》 （以下简称"《公司章程》"）的规定。 表决结果：3 票同意、0 票反对、0 票弃权。 特此公告。 健尔康医疗科技股份有限公司 （一）审议通过《关于公司 2025 年半年度报告全文及摘要的议案》 监事会认为：公司 2025 年半年度报告的编制和审议程序规范合法，符合法 律、法规、《公司章程》和公司内部管理制度的各项规定，内容真实、准确、完 整 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-020 健尔康医疗科技股份有限公司 第二届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 健尔康医疗科技股份有限公司（以下简称"公司"）第二届董事会第十四次 会议于 2025 年 8 月 28 日以现场和通讯相结合的方式在公司会议室召开，会议通 知于 2025 年 8 月 18 日以书面方式送达。本次会议由董事长陈国平先生主持，应 到董事 9 人，实到董事 9 人。本次董事会的召集、召开和表决程序符合《中华人 民共和国公司法》（以下简称"《公司法》"）等有关法律、法规及《健尔康医 疗科技股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、董事会会议审议情况 经全体董事逐项审议，会议表决情况如下： （一）审议通过《关于公司 2025 年半年度报告全文及摘要的议案》 本议案已经董事会审计委员会全体同意，并同意提交公司董事会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）上披露 ...

健尔康医疗科技股份有限公司 信息披露管理制度 第一章 总 则 第一条 为规范健尔康医疗科技股份有限公司（以下简称"公司"）信息披露 行为，保护公司、股东、债权人及其他利益相关者的合法权益，根据《中华人民 共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司 信息披露管理办法》《上海证券交易所股票上市规则》（以下简称"《上市规则》"）、 《上海证券交易所上市公司自律监管指引第 2 号——信息披露事务管理》等法律 法规以及《健尔康医疗科技股份有限公司章程》（以下简称"《公司章程》"）的规 定，结合公司实际情况，制定本制度。 第二条 公司证券部是公司信息披露管理部门，负责信息披露相关事宜。 本制度所称"披露"或者"公告"，指公司或者相关信息披露义务人按照法 律、行政法规、部门规章、规范性文件及上海证券交易所（以下简称"上交所"） 其他规定在上交所网站和符合中国证监会规定条件的媒体发布信息。 本制度所称"及时"是指自起算日起或者触及披露时点的两个交易日内。 本制度所称"信息披露义务人"，是指公司及其董事、高级管理人员、股东、 实际控制人，收购人，重大资产重组、再融资、重大交易有关各方等自然人、 ...